Q1 EARNINGS: Thoratec hopeful for the future
This article was originally published in Clinica
Executive Summary
Heart assist device specialist Thoratec saw its top and bottom lines fall in Q1, but it still exceeded analyst expectations and consequently improved its sales and earnings outlook for the year. Q1 sales of $121.3m shrank 4% as reported, but came in ahead of consensus of $109.8m. Revenues also grew 4% at constant currency rates and excluding Japan, “where unusual order patterns impact reported growth,” according to the company.